Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.37 |
| ▸ | CKS1B | P61024 | 2/20 | 0.35 |
| ▸ | SKP1 | P63208 | 2/20 | 0.35 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 2/20 | 0.33 |
| ▸ | PREP | P48147 | 1/20 | 0.33 |
| ▸ | KCNK3 | O14649 | 3/20 | 0.33 |
| ▸ | KCNK9 | Q9NPC2 | 3/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | PTGIR | P43119 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | NTMT1 | Q9BV86 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL361792 | 0.90 | CKS1B (0.45) | GPR119CKS1BSKP1SKP2KCNK3 | |
| SCHEMBL14876725 | 0.85 | ALDH1A1 (0.38) | CNR1PTGIR | |
| SCHEMBL15110449 | 0.82 | GPR119 (0.41) | GPR119CKS1BSKP1SKP2KMT2A | |
| SCHEMBL362106 | 0.81 | POLB (0.35) | KMT2APOLBL3MBTL1PTGIR | |
| SCHEMBL15968405 | 0.81 | CKS1B (0.35) | GPR119CKS1BSKP1SKP2KMT2A | |
| SCHEMBL15110209 | 0.81 | CYP1A2 (0.39) | GPR119CKS1BSKP1SKP2KMT2A | |
| SCHEMBL362961 | 0.79 | GPR119 (0.41) | GPR119CKS1BSKP1SKP2KMT2A | |
| SCHEMBL15117344 | 0.79 | GPR119 (0.37) | GPR119CKS1BSKP1SKP2KMT2A | |
| SCHEMBL15110828 | 0.79 | CKS1B (0.34) | GPR119CKS1BSKP1SKP2KMT2A | |
| SCHEMBL15111310 | 0.78 | GPR119 (0.39) | GPR119CKS1BSKP1SKP2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2593452-B1 | IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS | NOVARTIS AG (CH) | 2017-01-18 | — | — | EP | disclosed |
| US-9132127-B2 | Substituted pyrido[2,3-B]pyrazines as IP receptor agonists | NOVARTIS AG (CH) | 2015-09-15 | — | — | US | disclosed |
| US-20150005311-A1 | IP receptor agonist heterocyclic compounds | NOVARTIS AG (CH) | 2015-01-01 | — | — | US | disclosed |
| EP-2802583-A1 | FUSED PIPERIDINES AS IP RECEPTOR AGONISTS FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) AND RELATED DISORDERS | Novartis AG (CH) | 2014-11-19 | — | — | EP | disclosed |
| US-20140243346-A1 | IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS | NOVARTIS AG (CH) | 2014-08-28 | — | — | US | disclosed |
| US-8754085-B2 | Pyrido[2,3-b]pyrazine compounds useful as IP receptor agonist | NOVARTIS AG (CH) | 2014-06-17 | — | — | US | disclosed |
| WO-2013105063-A1 | FUSED PIPERIDINES AS IP RECEPTOR AGONISTS FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) AND RELATED DISORDERS | NOVARTIS AG (CH) | 2013-07-18 | — | — | WO | disclosed |
| EP-2593452-A1 | IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS | Novartis AG (CH) | 2013-05-22 | — | — | EP | disclosed |
| US-20130102611-A1 | IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS | NOVARTIS AG (CH) | 2013-04-25 | — | — | US | disclosed |
| WO-2012007539-A9 | IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS | NOVARTIS AG (CH) | 2012-11-01 | — | — | WO | disclosed |
| WO-2012007539-A1 | IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS | NOVARTIS AG (CH) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005311-A1 | IP receptor agonist heterocyclic compounds | PTGIR, GPR68, ACVR1 | GPR119 118/4885CKS1B 2504/4885SKP1 3896/4885 |
| US-20140243346-A1 | IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS | PTGIR, ACVR1, PTGFR | GPR119 201/4885CKS1B 2862/4885SKP1 3883/4885 |
| US-20130102611-A1 | IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS | PTGIR, ACVR1, PTGFR | GPR119 201/4885CKS1B 2862/4885SKP1 3883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.